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ABSTRACT
Despite significant advances made in epigenetic
research in recent decades, many questions
remain unresolved, especially concerning cause
and consequence of epigenetic marks with respect
to gene expression modulation (GEM). Technologies
allowing the targeting of epigenetic enzymes to
predetermined DNA sequences are uniquely suited
to answer such questions and could provide potent
(bio)medical tools. Toward the goal of gene-specific
GEM by overwriting epigenetic marks (Epigenetic
Editing, EGE), instructive epigenetic marks need to
be identified and their writers/erasers should then
be fused to gene-specific DNA binding domains.
The appropriate epigenetic mark(s) to change in
order to efficiently modulate gene expression
might have to be validated for any given chromatin
context and should be (mitotically) stable.
Various insights in such issues have been obtained
by sequence-specific targeting of epigenetic
enzymes, as is presented in this review. Features
of such studies provide critical aspects for further
improving EGE. An example of this is the direct
effect of the edited mark versus the indirect effect
of recruited secondary proteins by targeting epigen-
etic enzymes (or their domains). Proof-of-concept of
expression modulation of an endogenous target
gene is emerging from the few EGE studies
reported. Apart from its promise in correcting
disease-associated epi-mutations, EGE represents
a powerful tool to address fundamental epigenetic
questions.
INTRODUCTION
Epigenetics is gaining momentum in nearly all biomedical
research ﬁelds, and substantial knowledge of the epigen-
etic marks (e.g. DNA methylation and post-translational
histone modiﬁcations) and enzymes involved in reading,
writing and erasing of such marks have been obtained
(1–5). The majority of the data reported so far, however,
does not provide insights in, e.g., the relative importance
of the marks with regard to gene expression control, nor in
the order of events. In general, the performed studies tend
to be descriptive and epigenetic questions related to cause
or consequence effects of epigenetic marks with respect to
gene expression modulation (GEM) are under debate
(6–8). In light of the fact that such fundamental questions
have only been addressed in a few studies, including
(9–11), targeting epigenetic enzymes to particular chroma-
tin landscapes will provide useful insights. This review sets
out to summarize the outcome of targeting approaches
with respect to the effect of epigenetic writers and
erasers on the chromatin state and/or on gene expression
(Figure 1 and Tables 1–3).
The general principle of DNA-sequence-speciﬁc target-
ing systems is the fusion of (a part of) an epigenetic
enzyme to a DNA binding domain (DBD) to enforce
the presence of this effector domain on a particular
DNA sequence (Figure 1). This target DNA sequence is
often located within an oligonucleotide, a plasmid or
integrated in a particular chromatin environment in the
genome of a cell. In addition to the induced epigenetic
changes, the effect of targeting epigenetic enzymes on
gene expression can be assessed by measuring gene expres-
sion levels of (reporter) genes that lie in close proximity of
the DBD recognition site. Most of the reported targeting
efforts make use of non-mammalian DBDs and (multiple
repeats of) their speciﬁc recognition sequences including
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the yeast Gal4-UAS system (12), the prokaryotic Tet
Repressor (TetR)-Tet Operator (TetO) (13), Lac
Repressor (LacR)-Lac Operator (LacO) (14,15) and the
LexA repressor-LexA operator system (16). Additionally,
some mammalian systems have been exploited to target
enzymes to native endogenous chromatin sites, like the
Methyl Binding Domain (MBD) of MeCP2 to target
enzymes to genomic sites consisting of hypermethylated
DNA (17,18), the DBD of Mixed Lineage Leukemia
(MLL) to force epigenetic enzymes to reside on endogen-
ous MLL target genes (19,20) and the DBD of NFkB to
affect NFkB targets (21).
All of the above mentioned systems, however, are
somewhat limited with regard to addressing biologically
relevant questions, because of the need to introduce
foreign DBD recognition sites in the host cells, or
because they are not speciﬁcally targeting one unique
site in the genome, but multiple endogenous target sites
of the DBD. To speciﬁcally bind one genomic address, as
explored by Artiﬁcial Transcription Factors (ATFs) (22),
various classes of DBDs can be engineered, such as
designer zinc ﬁnger (ZF) proteins (23), Triplex Forming
Oligos (TFOs) (24) and the recently described TALE
domains (25). Indeed, with the developments in the ﬁeld
of genome editing [where nucleases are fused to
sequence-speciﬁc DBD proteins to introduce site-speciﬁc
DNA cleavage: Methods of the Year 2011 (26)], the tar-
geting of epigenetic editors (writers or erasers) to a speciﬁc
gene has come within easy reach.
The effective binding of the (gene-speciﬁc) DBDs to
various euchromatin and heterochromatin targets has
been shown by fusing the DBDs to transcription
activating or repressive domains (VP64 or SKD, respect-











Figure 1. Targeted rewriting of epigenetic marks. Schematic ﬁgure shows the general concept of targeting epigenetic enzymes. In the middle, an
example of a certain locus harboring a DBD recognition site (black triangle) is shown. Lollypops represent either unmethylated (open) or methylated
(ﬁlled) CpGs. Histones and their tails are also represented. Histone tails can be post-translationally modiﬁed and as such are associated with a
repressed chromatin state (represented by the ﬁlled black dots), or with an active chromatin state (represented by open black circles). The upper and
lower ﬁgures show the induced change in gene expression by targeting a DBD fused to an epigenetic enzyme involved in changing the epigenetic
composition (histone modiﬁcations or DNA methylation), thereby causing gene activation (top) and repression (bottom). In the epigenetic enzymes,
CD=catalytic domains and RD = recruiting domains are indicated. Black arrows show the action of the CD of the epigenetic enzymes, dashed
arrows show the possible recruitment of other proteins or capturing by other proteins (star, top; shape, bottom).
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repress (23) target gene expression. Despite their success
(22,23,28), ATFs are likely to function only transiently
and active gene-speciﬁc overwriting of epigenetic marks
by targeting epigenetic enzymes or domains thereof
(Epigenetic Editing, EGE) might provide advantages with
respect to long-term modulation of gene expression. Apart
from obtaining sustained GEM, other advantages of EGE
include upregulation by allowing natural expression mech-
anisms to occur, as opposed to mere overexpression as
obtained by gene therapy or ATFs. Moreover, the
approach of EGE is uniquely suited to investigate func-
tions of epigenetic writers and erasers and to elucidate
consequences of epigenetic marks at any given chromatin
environment, providing insights in gene expression regu-
lation mechanisms. In this review, an overview of studies
on sequence-speciﬁc and the few gene-speciﬁc targeted epi-
genetic editors will be presented. Also, some points from
these studies will be highlighted that will further improve
gene-speciﬁc EGE efforts. Although essential information
on chromatin behavior has been obtained by targeting
epigenetic readers as well, this review will only focus on
direct modulation of epigenetic marks by the implicit tar-
geting of writers and erasers.
GENE EXPRESSION MODULATION WITH
TARGETED EPIGENETIC EDITORS
A substantial amount of studies on targeting epigenetic
enzymes has provided strong indications that epigenetic
editors can be targeted to obtain a change in gene expres-
sion. These studies, as discussed in this review, have been
using diverse experimental designs ranging from oligo-
nucleotides to endogenous genes in the natural chromatin
context. Thus far, the observed effects of targeted epigen-
etic enzymes (including histone modifying enzymes) have
been mainly obtained by co-transfection experiments.
Such experiments more closely resemble the endogenous
situation than test-tube oligonucleotides experiments,
since the fusion proteins (and their target plasmid)
encounter endogenous factors that might play a role, or
are even required, in changing essential epigenetic
marks and/or in obtaining GEM. However, the use of
cotransfections to analyse the effects of targeted histone
modiﬁers is subject of debate. Whereas it has been
reported that plasmids are not suitable for establishing
the effects of targeting histone modifying enzymes
because of the lack of chromatinization (29), others
show by ChIP that a molecular effect of targeting
histone modifying enzymes can be observed, indicating
that histones can get associated with the plasmid (30,31).
These latter studies conﬁrm nuclease-digestion experi-
ments demonstrating the association of nucleosomes on
plasmid DNA (32–34). More informative data, however,
can be derived from targeting epigenetic editors to exogen-
ous sites (usually including a reporter gene) integrated in
the chromatin context of cells. Although this approach is
also artiﬁcial and integrated sites are more susceptible to
epigenetic silencing, it provides insights in the effect of
induced changes on the chromatin context and is
suitable to address heritability issues. True EGE, where
a single endogenous gene is targeted, obviously provides
the most relevant information and the few studies pub-
lished so far will be discussed in more detail.
As described below, although not all of the targeting
studies describe effects on both molecular epigenetic
level and GEM, some (including the EGE studies)
clearly indicate the causal relationship between the
rewritten mark and GEM. Because of differences in
experimental design (such as the type of DBD or design
and expression of the construct) it is difﬁcult to compare
efﬁcacy of targeted GEM between studies. It is tempting
to speculate that an absence of effect on gene expression
upon inducing a change in one epigenetic mark can be
explained by the native chromatin context, as exempliﬁed
by the protection of DNA for CpG methylation when
histone 3 lysine 4 is methylated, which thus might
prevent spreading (35–37). Other marks that remain
present in the chromatin context of the targeted gene
might recruit enzymes to restore the initial epigenetic
proﬁle. In this regard, it is currently unclear if more
than one mark needs to be changed to facilitate an effect-
ive change in gene expression in the endogenous situation.
Furthermore, the change of more than one epigenetic
mark could very well be required for heritability of the
effect, which would be of importance for therapeutic
approaches in particular. Nevertheless, as described in
this ﬁrst part, promising results have been obtained by
the active change of just one epigenetic mark and
approaches to further improve EGE arising from such
studies will be discussed in the second part.
Downregulation of gene expression via rewriting
of epigenetic marks
In general, targeted epigenetic silencing has advantages
over siRNA approaches, which are currently
widely exploited for various clinical phenotypes, as
reviewed in (38), but which are generally transient and
suffer from target-independent effects (39,40). An
alternative (synergistic) approach to downregulate the
expression of a gene of interest is by ATFs, which might
proof efﬁcient as only two copies of DNA need to be
targeted in every cell, as opposed to numerous
continuously produced mRNA molecules. Although
signiﬁcant repression has been achieved for various
endogenous genes by fusions of ZFs to the KRAB
domain (23,28), the KRAB domain does not have
enzymatic activities by itself and therefore does not
directly interfere with the epigenetic context at the target
site. In this respect, direct targeting of epigenetic enzymes
to endogenous target sequences (EGE) is more relevant,
both for biological questions as well as for the potential
use of EGE as a therapeutic approach in the future. In this
section, studies on repressive effector domains targeted to
actively interfere with epigenetic marks in order to repress
gene expression are discussed.
Targeted DNA methyltransferases
DNA hypermethylation, especially around the
transcription start site and exon 1 (41,42), is strongly
associated with inactive genes. Moreover, DNA
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methylation is in principle faithfully inherited during
mitosis, and has been reported to serve as a strong
molecular mark for gene silencing memory (43–45).
Therefore, to permanently downregulate the expression
of a gene, targeting DNA methyltransferases (MTases) is
an obvious choice. Some alternative gene-speciﬁc
technologies to induce DNA methylation have been
described, including RNA-directed (46) and methylated
oligo-induced (47) methylation, but the general
applicability of such approaches to silence any gene of
interest is unclear. Nowadays, DBDs can be engineered
to speciﬁcally bind virtually any gene (22,23) to target
transcriptional repressors to these genes, subsequently
decreasing gene expression. Indeed, upon fusion of such
engineerable DBDs to the KRAB domain, effective
reduction of oncogene expression (resulting in reduced
tumorigenicity) was shown (28). Thus, fusion of DNA
MTases to such domains offers an appealing approach
for inducing inheritable gene silencing. In fact, DNA
MTases have been extensively studied in fusions to ZFs
(Table 1), as also reviewed in (62).
Indeed, upon targeting by fusion to gene-speciﬁc (ZFs
or TFOs) or sequence-speciﬁc (Gal4) DBDs, both the
prokaryotic DNA MTases M.SssI, M.HhaI and
M.HpaII as well as the catalytic domains (CDs) of the
mammalian enzymes mDnmt3a and mDnmt3b showed
efﬁcient preferential DNA methylation of target sites in
oligonucleotides (48,50–53) or on reporter plasmids
(30,50,52,53,55) and when assessed, the targeted DNA
methylation upon cotransfections was correlated to
repression of reporter gene expression (Table 1). The
ability of a ZF fused to a prokaryotic DNA MTase to
cause preferential DNA methylation at an endogenous
mammalian target site was observed for M.SssI in the
context of yeast chromatin (49). Noteworthy, the ZF
binding site itself was not methylated, indicating
protection from direct DNA methylation by the ZF
binding. As yeast cells have no endogenous DNA
methylation system, targeting speciﬁcity can be
easily investigated. In this respect, this yeast study—as
conﬁrmed in some of the other studies (48,49,52)—
revealed additional aspeciﬁc background DNA
methylation, which will be further discussed in
‘TOWARD SPECIFIC GENE EXPRESSION
MODULATION—The effector domain’.
To increase speciﬁcity of the targeted DNA methylation
by prokaryotic enzymes, ZFs were fused to less active
mutants of these prokaryotic DNA MTases
(M.HhaIQ237G and M.HpaIIF35H (52). In contrast to
ZF-M.HhaIQ237G, ZF-M.HpaIIF35H was able to induce
DNA methylation on its target site, integrated in the
bacterial genome. Moreover, when targeting a site
integrated in the mammalian genome, ZF-M.HpaIIF35H
could induce targeted DNA methylation as well as
downregulation of the reporter gene (54). Interestingly,
the histone modiﬁcation state of the ZF target site
accordingly changed into a repressive state, as an
enrichment of H3K9me2 and a reduction of H3K4me3
was observed at the site of the integrated reporter gene
where DNA methylation was induced (54). This indicates
that active change of one epigenetic mark (in this case
DNA methylation) can cause a cascade of changes,
which might reinforce the repressive state of the chromatin
at the target gene. Such a reinforced repressive chromatin
state could explain the observation of remaining DNA
methylation at the target site after several cell passages.
Moreover, the stable DNA methylation state was
associated with stable reporter gene repression at least
up to 17 days after the expression of ZF-M.HpaIIF35H
was no longer detected at both the RNA and protein
level (at 6 or 7 days after transfection, respectively) (54).
This sustained DNA methylation and repression of gene
expression is indicative of the DNA methylation induced
by ZF-M.HpaIIF35H being inherited through cell
Table 1. Targeted DNA methylation editors
Enzyme DBD Target EGE GEM References
M.SssI ZF Oligo, endogenous target (yeast) 3 n.a. (48,49)
TFO Plasmid DNA (cell free) 3 n.a. (50)
M.HhaI ZF Oligo (cell free) 3 n.a. (51–53)
Plasmids in bacteria 3 n.a. (52,53)
Integrated (bacteria) 5 n.a. (52)
M.HpaII ZF Oligo, plasmid DNA (cell free) 3 n.a. (51,52)
Plasmids/integrated (bacteria) 3 n.a. (52)
Integrated (mammalian) 3 # (52,54)
mDnmt3a FL Gal4 Reporter plasmid (mammalian) 5 # (30)
mDnmt3a CD Gal4 Reporter plasmid (mammalian) 3 # (55)
ZF Reporter plasmid (mammalian) 3 # (55)
ZF Viral DNA 3 n.a. (55)
hDnmt3a CD ZF Mitochondrial DNA 3 n.a. (56)
Endogenous target (mammalian) 3 # (57)
mDnmt3b CD Gal4 Reporter plasmid 3 # (55)
Tet1 Gal4 Integrated (mammalian) n.a. # (58)
5-MCDG RXRa-receptor Integrated (mammalian) 3 " (59)
LexA Integrated (mammalian) n.a. 5 (60)
TDG NFkB DBD Endogenous targets (mammalian) 3 " (21)
VP64 ZF Endogenous target (mammalian) 3 " (61)
5, no effect; n.a., not assessed; 3, effect reported; #, downregulation; ", upregulation.
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divisions. This study thus provides proof-of-concept that
targeted DNA methylation can be exploited for sustained
gene repression.
Compared with prokaryotic MTases, mammalian DNA
MTases, i.e. Dnmt1, 3a and 3b, display several advantages
when considered for use in targeted DNA methylation of
the mammalian genome: although, like M.SssI,
mammalian DNA MTases can methylate all CpG
sequences without any further sequence-restrictions, the
low catalytic activity of the mammalian enzymes (63)
might better allow restriction of methylation to targeted
CpGs by fusion to DBDs. In addition, since being
mammalian, the MTase activity is probably not inﬂuenced
by DNA-histone interactions that theoretically might
hamper the prokaryotic DNA MTases, as these originate
from histone-less organisms (64). Moreover, mammalian
enzymes are more likely to recruit other mammalian
proteins important for reinforcement of transcriptional
repression. This is nicely exempliﬁed by the Gal4-
mDnmt3a full-length cotransfection study (Table 1):
although no detectable DNA methylation was induced
at the target region by this construct, repression of
reporter gene expression was observed (30). Recruitment
of endogenous co-factors has been observed for this and
several other epigenetic effector domains and will be
discussed later. Last but not least, the domain will evoke
less immunogenicity since it is less foreign to the organism.
The ability to cause preferential DNA methylation at a
cellular target site was observed for a ZF fused to
hDnmt3a CD, targeting mitochondrial DNA (56). In
this study, 23% of the clones analysed by bisulﬁte
sequencing showed preferential methylation at the
cytosine directly adjacent to the ZF binding site (56).
Another interesting parameter that has been addressed
in this study is spreading of the epigenetic mark, which
was observed within a region of at least 120 bp
surrounding the ZF target site (56). In another study,
where DNA methylation was targeted to successfully
methylate viral DNA upon cellular infection, spreading
up to 380 bp on either site of the DBD recognition site
has been observed (55). However, it is not directly clear
whether the observed induction of distant DNA
methylation in these studies is truly because of spreading
or because of the ﬂexibility of the targeting construct or
the target DNA.
Only very recently, the ﬁrst gene-speciﬁc ZF-targeted
DNA methylation was reported in the nuclear chromatin
context for the tumor suppressor gene MASPIN and the
oncogene SOX2 (57). Upon targeting the CD of Dnmt3a
to the promoter of the MASPIN gene, pronounced
targeted DNA methylation (of 50%) occurred for two
target CpGs. In addition, differential positioning of
induced DNA methylation was obtained by this EGE
approach. The targeted DNA methylation was sufﬁcient
to efﬁciently downregulate MASPIN expression, with up
to 90% repression observed in single clones. Efﬁcient
repression without dense DNA methylation is in line
with other observations, like for p53 where induced
DNA methylation of a single-speciﬁc CpG was shown to
severely decrease gene expression (65). Interestingly, the
observed MASPIN downregulation was stably inherited:
up to 50 days post-infection, when the expression of the
ZF-Dnmt3a CD fusion was barely detectable, gene
expression was still repressed. Moreover, treating cells at
this time point with the DNA methylation inhibitor 5-
azadeoxycytidine released the repression, indicating that
the induced DNA methylation is still present. Indeed,
methylation patterns remained similar to the patterns
observed soon after transductions. Furthermore,
knockdown of UHRF1 expression, a protein involved in
DNA methylation maintenance, caused signiﬁcant re-
expression of MASPIN. The ﬁndings were extended to
the oncogene SOX2, which could also be efﬁciently
repressed upon targeting Dnmt3a CD to its promoter by
fusion to another ZF. By making use of a doxycycline
inducible promoter, expression of the ZF-Dnmt3a CD
could be cleared after 48 h, allowing the cells to recover
from repression. Interestingly, the ZF-Dnmt3a cells did
not recover cell proliferation, while cells conditionally
expressing a ZF-KRAB derivative did recover. Studies
like these indicate the beneﬁt of using EGE over targeting
the KRAB domain.
Targeted repressive histone modifying enzymes
As an alternative (or synergistic) approach to the
introduction of DNA methylation at transcription start
sites, repression of gene expression can be achieved by
targeted modiﬁcation of histone tail residues. In this
respect, repressive chromatin covered by histone H3K9
methylation, exhibits a chromatin state that is proposed
to be able to spread its epigenetic composition for instance
via Heterochromatin Protein 1 (HP1)-induced heterochro-
matinization (66,67). As such, H3K9 MTases (such as
Setdb1, G9a and Suv39H1/SU(VAR)3-9) are of interest
to fuse to DBDs for repression of target gene expression.
Furthermore, histone H3K27 methylation represents a
chromatin state related to Polycomb group protein
(PcG) regulated genes that become stably silenced
during differentiation and cell-fate determination, which
makes H3K27 MTases (like Ezh2 or vSet) other
interesting candidates for targeted repression of gene
expression. Indeed, H3K9, H3K27 and H3K36 MTases
(Set2 and Smyd2) as well as an H3K4 demethylase
(LSD1) have been targeted leading to gene repression in
all cases where gene expression was assessed (Table 2).
Interestingly, lysine residues like H3K9 and H3K27 can
be either acetylated or methylated, and deacetylation of
acetylated histone lysine residues is required before the
induction of histone methylation on these lysine residues
can take place (84). It has long been thought that because
acetylation neutralizes the positive charge on the histones,
this modiﬁcation facilitates the open conﬁguration of the
chromatin at actively expressed regions in the chromatin
(85,86). Indeed, hypoacetylation is found at promoter sites
of genes with low or no expression levels, whereas
acetylated histone tails are mainly associated with active
genes (84,87). In addition to this ‘charge hypothesis’,
acetylation also recruits activating protein complexes
(including chromatin ‘readers’) by changing the histone
modiﬁcation composition of the chromatin (88,89).
Thus, to silence genes through EGE, also HDACs are
among the candidate enzymes to be targeted. HDACs of
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class I (HDAC1, 2 and 3) as well as the sirtuin SirT1
(NAD+ dependent, class III) have been targeted in
cotransfection studies using the Gal4 or LexA DBD and
indeed reduced gene expression (Table 2).
Although promising, most studies were not intended to
assess the actual induction of the histone mark and no
conclusions can be drawn from these studies regarding
causal relationships between histone marks and
gene expression. In contrast, the anticipated targeted
change of histone modiﬁcations was assessed and
reported for Setdb1 (30) upon cotransfections and for
Sirt1 (75), LSD1 (77), G9a (78) and Ezh2 (76,81)
targeted to integrated target sites (Table 2). Accordingly,
these changes in epigenetic marks were associated with
repression of gene expression.
Interestingly, targeting of Gal4 fused to Sirt1 (75),
G9a (78) and Ezh2 (81) to integrated target sites, caused
other changes in histone marks in addition to the ones
anticipated, as also described for targeted DNA
methylation. This again might indicate that the change
of one mark can induce a cascade of changes in chromatin
modiﬁcations which probably reinforces the repressed
state and might also add to the persistence of repression.
Indeed, mitotically inherited repression of target gene
expression was noted at least up to 4 days after clearance
of the tetracycline-inducible expression of the Gal4-Ezh2
fusion protein in human cells (81), associated with both
the anticipated H3K27 methylation and additional
H3K4 demethylation. In a murine study, Gal4-Ezh2 did
not change other marks than H3K27 methylation (76). In
fact, although targeting Ezh2 was shown to recruit
Dnmt3a to the integrated target site, no DNA methylation
was observed and permissive chromatin marks
(H3K4me2, H3Ac) remained present. The absence of
DNA methylation, despite the presence of Dnmt3a,
might be explained by the presence of H3K4 methylation,
as this mark seems to prevent DNA methylation (35–37)
and as such might need to be removed by a speciﬁc histone
demethylase before repression of gene expression can take
place. In this respect, targeting of TetR-LSD1 to an
artiﬁcial chromosome resulted in demethylation of
H3K4me3 (without affecting H3K9/K27 methylation)
and induction of gene expression (77). However, in
another study, targeting of Gal4-LSD1 to a target
integrated in mammalian cells, with the aim to allow
DNA methylation to be induced upon targeting of Ezh2,
was not successful (76). It might be that this discrepancy is
caused by the chromatin context of the artiﬁcial
chromosome where LSD1 was targeted to by fusion to
TetR, which made it easier to reach the target or to
affect the histone modiﬁcation levels. However, since the
experimental designs were so different, it is difﬁcult to
compare the two studies.
The crosstalk between histones and DNA methylation
(90,91) has also been described for other histone
marks than H3K4 methylation. In this respect, the
Histone Methyl Transferase (HMT) G9a, which induces
H3K9 methylation, HP1 binding, local heterochromatin
formation and gene silencing, can also recruit DNA
MTases Dnmt3a and 3b which catalyse de novo DNA
methylation (92,93). Similarly, in addition to loss of
H3K9 methylation at major centromeric satellites in
Suv39h knock-out embryonic stem cells, also a decrease
in Dnmt3b dependent CpG methylation has been
observed (94). Targeting of such writers might thus
result in efﬁcient repression of gene expression. Indeed,
gene-speciﬁc ZF-targeted histone modiﬁcations result in
repression of a target gene in the endogenous chromatin
context by targeting G9a/Suv39H1 or a histone
deimination domain (29,95). Targeting of G9a or
Suv39H1 by fusion to a three-ﬁnger ZF designed to bind
the gene of interest (VEGF-A), provides the ﬁrst example
of ZF-mediated EGE of an endogenous gene (29). This
VEGF-A ZF, when fused to a transcriptional activation
domain like Viral Protein 16 (VP16) of HSV (Herpes
simplex virus type 1), caused upregulation of endogenous
Table 2. Targeted repressive histone modifying enzymes
Enzyme Aka (68) DBD Target EGE GEM References
HDAC1 Gal4 Reporter plasmid (in vial) n.a. 3 (69)
Reporter plasmid n.a. 3 (70,71)
HDAC2/RPD3 Gal4 Reporter plasmid n.a. 3 (71,72)
LexA Reporter plasmid n.a. 3 (73,74)
HDAC3 Gal4 Reporter plasmid n.a. 3 (71)
Sirt1 Gal4 Reporter plasmid n.a. 3 (75)
Integrated (mammalian) 3 3 (75)
LSD1 Gal4 Integrated (mammalian) 5 n.a. (76)
TetR Integrated (artiﬁcial chromosome) 3 3 (77)
Setdb1 KMT1E Gal4 Reporter plasmid 3 3 (30)
G9a KMT1C Gal4 Integrated (mammalian) 3 3 (78)
ZF Endogenous target 3 3 (29)
Suv39H1/SU(VAR)3-9 KMT1A Gal4 Reporter plasmid n.a. 3 (79,80)
ZF Endogenous target 3 3 (29)
Ezh2 KMT6 Gal4 Integrated (mammalian) 3 3 (81)
3 n.a. (76)
vSet Gal4 Reporter plasmid n.a. 3 (82)
Set2 KMT3A LexA Reporter plasmid n.a. 3 (73)
Smyd2 KMT3C Gal4 Reporter plasmid n.a. 3 (83)
Aka, also known as; 5, no effect; n.a., not assessed; 3, effect reported.
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VEGF-A expression (96) and has been further
investigated in phase II clinical trials after fusion to the
activator p65. Despite a lack of improved therapeutic
effect over placebo treatment (97), these efforts dem-
onstrate the feasibility of targeting genes in a clinical
setting by ZFs. Swapping the transcriptional activation
domain with the catalytic C-terminal domain of H3K9
MTase G9a (N-terminal 828 amino acids (aa) removed)
or with smaller N-terminal deletions (75 aa or 148 aa)
of Suv39H1, caused induction of at least H3K9me2 as well
as repression of the endogenous target gene (29). The
effect of the H3K9 MTases (inducing the anticipated
mark and repressing gene expression upon targeting)
was validated by us for another endogenous gene by
fusing the enzymes to another ZF (Falahi et al., submitted
for publication). For VEGF-A, increased levels of
H3K9me2 were observed throughout the investigated
region, up to 900 bp away from the ZF binding site
upon targeting either Suv39H1 (75 aa N-terminal) or
the CD of G9a (29). This indicates that the targeting of
an H3K9 MTase enables the activation of an endogenous
mechanism spreading the H3K9 methylation marks and
thereby reinforcing repression. Interestingly, in this study
and the one on targeted deimination by Cuthbert et al.
(95), the targeting construct was delivered to the cells via
transient transfection of an expression plasmid, whereas
the only other example of true endogenous EGE delivered
the construct virally (57). Unfortunately, the observed
effects were not followed in time, which would have
been interesting because prolonged effects would indicate
that the targeted induction of the mark is mitotically
inherited.
Induction of gene expression via rewriting of
epigenetic marks
Also for induction of gene expression, to reactivate
epigenetically silenced genes (for example tumor
suppressor genes in cancer), there is a variety of
possibilities. The achievements obtained by targeted
DNA demethylation, locus-speciﬁc addition of acetyl
groups to histone tail residues, methylation of H3K4 or
H3K79 and demethylation of H3K9 or H3K27 will be
discussed in this part (Tables 1 and 3).
Targeted ‘DNA demethylases’
To achieve long term re-expression, it seems apparent that
the removal of DNA methylation is an important step,
at least around the transcription start site and exon 1
of the target gene (41,42). However, until quite recently
it was not generally accepted that active DNA
demethylation occurs in mammals, even though
examples had been described of both global and locus-
speciﬁc active DNA demethylation, as reviewed in (112).
In this respect, straightforward mammalian effector
domains to obtain targeted DNA demethylation are not
available. Now that the concept of active DNA
demethylation in mammals is increasingly accepted,
efforts to identify mammalian proteins associated with
the process of active DNA demethylation resulted in
interesting candidates for targeted removal of DNA
methylation marks as reviewed in (112,113). In fact,
several mechanisms and proteins were described to be
associated with DNA demethylation. In plants,
enzymes involved in DNA demethylation are relatively
well established. Repressor of silencing 1 (Ros1),
Demeter (DME) and Demeter-like proteins (DML2,
DML3) are unambiguously associated with active DNA
demethylation via base excision repair (BER) in plants
(114,115). Interestingly, although other epigenetic plant
enzymes have been shown to function in a mammalian
setting (29), no efforts were reported on expressing or
targeting the plant CpG demethylation enzymes in
mammalian cells.
Potential mechanisms of active DNA demethylation in
mammals, for which some indications have been
described, are (i) direct removal of the methyl group;
(ii) 5meC glycosylation followed by BER (like in plants);
(iii) deamination followed by mismatch repair; and
(iv) nucleotide excision repair (112,116). However, most
of these mechanisms are still under debate. One
mechanism that is now accepted to play a role in DNA
demethylation is oxidation of 5-methylcytosine to
5-hydroxymethylcytosine (5hmC) by the Tet enzymes.
The biological role of 5hmC itself is not fully known
yet. However, the 5hmC mark has been associated with
active genes (117), speciﬁcally at the promoter (118) but
also in the gene bodies (119,120). Similarly, ChIP-seq
studies demonstrated Tet1 to be present on genes
occupied by H3K4me3 (active), H3K27me3 (inactive) or
both (bivalent domains) and promoter activity can not be
predicted by Tet1 binding (58). For EGE purposes, it is
noteworthy to mention that 5hmC has been proposed to
be an intermediate in the active DNA demethylation
pathway (121). Consistent with this, intermediates that
might be formed in the process of converting 5hmC to
be eventually replaced by an unmodiﬁed cytosine were
detected recently (122).
Interestingly, upon targeting of Tet1 to ﬁve
Gal4-binding sites integrated in mammalian cells,
repression of the targeted integrated reporter gene was
observed (58). Also recruitment of Sin3a, a protein that
is part of a transcriptional repression complex could be
detected. Unfortunately, this targeting study did not
investigate effects on the DNA methylation status of
CpGs in the targeted site. In addition, Tet1 was not
targeted to hypermethylated (inactive) genes, so its
effects on gene expression in a heterochromatin context
are currently largely unknown.
As also suggested in one of the many reviews about
DNA demethylation (116), targeting candidate DNA
demethylases of the proposed possible pathways to
speciﬁc genes in different chromatin contexts will
provide more insights into the enzyme or enzymes that
can truly actively demethylate methylated CpGs.
However, only a few studies have employed targeting of
potential DNA demethylases so far, of which one not even
intentionally: upon overexpression of 5-MCDG, presently
known as Thymine DNA Glycosylase (TDG), the protein
associated with the retinoid receptor RXRa (59).
A reporter transgene was bound by this receptor and
(consequently) DNA demethylation and upregulation of
10602 Nucleic Acids Research, 2012, Vol. 40, No. 21
Downloaded from https://academic.oup.com/nar/article-abstract/40/21/10596/2411736
by University of Groningen user
on 27 March 2018
the expression of this gene were observed. Interestingly,
TDG was recently fused to the DBD of NFkB, which also
led to some DNA demethylation of endogenous NFkB
target genes and an increase in target gene transcription
(21). In contrast, in another study, aiming to prevent
silencing, no effect on the expression of an integrated
target gene was seen upon stable transfection of LexA-
MCDG in mammalian cells (60).
Alternatively, a ZF targeting study in mammalian
cells reported on DNA demethylation induced by
targeting a transcriptional activator (VP16-tetramer;
VP64) to an endogenous gene (61). Effectively, a gene-
speciﬁc upregulation of gene expression of 25- to 125-
fold on mRNA level was achieved, associated with DNA
demethylation of up to 70% of the targeted CpGs.
Although it might be suggested that the DNA de-
methylation is a secondary effect of the VP64-induced
transcription, the precise location of demethylation,
which is strictly determined by the orientation of the
effector domain, would argue against this. Still, it needs
to be further investigated whether the DNA de-
methylation is due to active DNA demethylation by
VP64 or its recruited proteins, or whether the effect is
merely a consequence of steric hindrance by recruited
protein complexes preventing Dnmt1 from copying
methylation to the daughter strand upon cell division. In
plants, transient transfection of gene-speciﬁc ZFs fused to
VP64 even resulted in heritable (at least two subsequent
generations) activation of gene expression of the targeted
gene (123). The sustained effect observed here might also
be associated with epigenetic changes like DNA
demethylation, although this was not addressed in the
speciﬁc study.
Targeted activating histone modifying enzymes
Although DNA methylation provides a powerful silencing
memory, it is not necessarily a lock for gene expression
and many genes have been found to be upregulated
despite their DNA hypermethylation status after
treatment of cells with HDAC inhibitors as described in
(43) and references therein. Thus, instead of (or in
addition to) DNA demethylation, gene-speciﬁc removal
of repressive histone marks and/or induction of activating
histone marks might achieve efﬁcient and lasting
upregulation of target gene expression. Histone modifying
enzymes that are likely to be of interest for obtaining
targeted activation of gene expression are histone
acetyltransferases (HATs; such as p300, P/CAF, CBP
and GCN5) and histone methyltransferases methylating
histone tail residues H3K4 or H3K79 (for instance
Meisetz and Ash1 or Dot1/Dot1L, respectively). Several
‘activating’ histone modifying enzymes have been targeted
to predetermined target sites (see Table 3 for an overview)
within reporter plasmids, integrated within host genomes
or to endogenous target sites by using the endogenous
DBDs MLL or MBD.
Irrespective of the context of the target gene, upre-
gulation of gene expression was seen for most of the
activating histone modifying enzymes that were targeted
(p300, P/CAF, CBP, GCN5, Meisetz, Ash1 and Dot1).
Since most cotransfection studies intended to examine
the role of co-activators, molecular chromatin marks
were generally not studied (and if so, to a low extent).
Importantly, the one cotransfection study that assessed
molecular chromatin marks on plasmid level upon
targeting of an activating histone modifying enzyme
indeed showed an increase in acetylation by targeted
p300 (31).
Interestingly, despite using the same DBD, different
genes can be affected when (domains of) other enzymes
are fused. Namely, when the HAT domain of CBP in a
fusion of CBP to MLL was exchanged for the HAT
domain of either P/CAF or GCN5, other genes seem to
be upregulated than with the CBP HAT domain, since
different (less differentiated) cell surface markers are
expressed (20). Thus, this indicates that the various
HATs each have their own substrates and/or that
depending on the chromatin context different functional
effects are induced.
Table 3. Targeted activating histone modifying enzymes
Enzyme Aka (68) DBD Target EGE GEM References
p300 KAT3B Gal4 Reporter plasmid n.a. 3 (98–101)
Reporter plasmid 3 3 (31)
LexA Integrated (mammalian) n.a. 3 (60)
MBD Endogenous targets n.a. 3 (18)
PCAF KAT2B Gal4 Reporter plasmid n.a. 3 (100)
LexA Integrated (mammalian) n.a. 3 (60)
MLL Endogenous targets n.a. 3 (20)
CBP KAT3A Gal4 Reporter plasmid n.a. 3 (102–106)
MLL Endogenous targets n.a. 3 (20,107)
GCN5 KAT2A MLL Endogenous targets n.a. 3 (20)
Meisetz Gal4 Reporter plasmid n.a. 3 (108)
Ash1 KMT2H Gal4 Integrated (drosophila) 3 3 (109)
LexA Integrated (mammalian) n.a. 5 (60)
Dot1/Dot1L KMT4 MLL Endogenous targets 3 n.a. (19)
LexA Integrated (yeast) n.a. 3 (110)
JMJD2D KDM4D MBD Endogenous targets 3 5 (17)
KIAA1718 KDM7A Gal4 Integrated (mammalian) 3 3 (111)
Aka, also known as; 5, no effect; n.a., not assessed; 3, effect reported.
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Whereas writing activating marks seems to be effective,
removal of repressive marks could also be of interest for
activation of genes. In fact, although (tri)methylation
marks were long thought to be relatively stable, various
enzymes have now been described to actively remove these
methylation marks (124,125). To actively remove the
repressive H3K27me3 mark, UTX (126,127) and JMJD3
(128) could be explored in targeting studies, but to the best
of our knowledge no such studies have been reported to
investigate the effect of removal of this particular mark.
However, other histone demethylases, demethylating
H3K9 and/or H3K27me2 (JMJD2D or KIAA1718) have
been studied in a targeted fashion and removal of the
marks was indeed demonstrated. Targeting of JMJD2D
to methylated endogenous genes by fusion to the MBD of
MeCP2 resulted in the intended reduction in H3K9me3 at
the analysed MLH1 gene, while no changes in H3K9me2
or DNA methylation levels were observed (17). Upon
analysing the effect on gene expression for this target
gene, it appeared that demethylation of H3K9me3 was
not enough to induce gene expression (17). Likewise, for
another target gene that was assessed (GSTP1), no
induction of gene expression could be shown. Molecular
marks were not analysed for this gene. The lack of
upregulation despite the change in H3K9 methylation
might be explained by the fact that no other (assessed)
marks changed. In contrast, targeted KIAA1718 (which
did cause upregulation of gene expression) showed an
increase of H3 acetylation levels, in addition to the
expected decreased level of H3K9me2 (111).
Another example of additional histone modiﬁcations
changing was observed when targeting drosophila Ash1.
Not only H3K4me2 levels decreased, H3K9me2 and
H4K20me2 marks were increased at a stably integrated
reporter gene in Drosophila S2 cells (109). However, the
induction of H3K9me2 and H4K20me2 is a known
function of dAsh1 in addition to the H3K4 methylation.
Interestingly, despite the additional induction of the two
marks that are associated with gene inactivity (H3K9/
H4K20 methylation), upregulation of the reporter gene
expression was still observed. The human homolog of
Ash1 was not able to change gene expression upon
targeting (60). Nevertheless, this is in line with ﬁndings
that human Ash1 does not methylate H3K4, but can
only mono- and di-methylate H3K36, which might be
insufﬁcient for GEM (129).
As becomes clear from Table 3, only a few studies
addressed the effect of targeting the ‘activating’ enzymes
both on modulation of the histone marks as well as on
gene expression, whereas others were not intended to
assess both. Studies investigating both of these features
can give some insights on whether the cause of activation
is the induction of the anticipated mark or merely
recruitment of other regulatory proteins (6,7). From the
studies reported so far, indications can be distilled that the
anticipated change in histone modiﬁcation by targeting of
p300 (31), Ash1 (109), Dot1L (19), JMJD2D (17) and
KIAA1718 (111) indeed led to increase in gene expression
of the targeted gene. However, only studies including the
targeting of a catalytic inactive counterpart of the domain
can ﬁrmly indicate a causative relationship between mark
and expression regulation and such studies have been
performed for DNA methyltransferases (55–57), Meisetz
(108), dAsh1 (109), vSet1 (82), Suv39H1 (29) and G9a (78)
as will be described below.
TOWARD EFFICIENT TARGETED GENE
EXPRESSION MODULATION
From the above, one can conclude that targeting
epigenetic enzymes is a feasible approach to determine
functional domains within epigenetic enzymes and to
investigate the effect of edited epigenetic marks. Various
reports also demonstrate that targeting epigenetic writers
or erasers indeed affect gene expression levels, and some
studies touched upon the chromatin context requirements.
So far, three papers on gene-speciﬁc EGE have been
published, describing the targeting of an epigenetic
writer to an endogenous locus through fusion to a gene-
speciﬁc DBD (29,57,95). Indeed, in these studies gene
expression was affected, with some indication of spreading
of the H3K9me2 mark (29) or mitotic stability of targeted
DNA methylation (57). Despite successful attempts on
rewriting epigenetic signatures to modulate gene
expression, the studies summarized above indicate that
many issues remain to be clariﬁed for this approach to
become robust. In this respect, questions to be addressed
include: (i) which epigenetic mark or combination of
marks needs to be induced/removed in order to efﬁciently
interfere with gene expression (given a particular
chromatin context); (ii) is the edited mark mitotically
stable or will the native epigenetic marks be restored
upon removal of the editor; and (iii) what is the inﬂuence
of the chromatin landscape in determining the outcome.
Depending on the envisioned epigenetic change, the most
optimal effector domains need to be engineered to
selectively, yet efﬁciently, execute its activity speciﬁcally
at the targeted site. Some of the studies summarized by
us (Tables 1–3) did address such efﬁciency and speciﬁcity
issues in more depth and will be discussed below.
Direct gene expression modulation
It is subject of a hot debate whether epigenetic marks are
the drivers of gene expression regulation or merely
associated with expression status (6–8). Indeed, for some
enzymes, targeting studies have shown that introducing
mutations in the CD or removal of this domain has little
or no effect on the induction of changes in gene expression
compared with the effect of their larger or full-length
counterpart proteins. This indicates that not in all cases
catalytic activity of the targeted enzyme is important for
an effect on gene expression. Obviously, different studies
target the effectors to different chromatin and cellular
contexts, and this context will signiﬁcantly inﬂuence the
outcome (as described for HATs below). Moreover,
differences might also be explained by a variation in
expression levels or nuclear entry of the constructs, but
this was not addressed in most studies. Despite the fact
that it is difﬁcult to distill general rules from the limited
amount of studies done so far, some evidence exists that,
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in particular cases, induction of the mark itself is likely to
be sufﬁcient to initiate gene expression differences.
In this respect, targeting of the CDs of Dnmt3a
(murine: aa 598-908, human: aa 592-909) and Dnmt3b
(murine: aa 557-859) was sufﬁcient to cause targeted
DNA methylation and repression of gene expression,
whereas targeting of catalytically dead mutants had no
effect on expression levels (55–57). Also with respect to
H3K4me3, replacing a Glycine residue with an Alanine
residue at aa position 278 in the catalytic PR/SET
domain (aa 246-365) completely abolished the activating
potential of Gal4-targeted Meisetz (108). Similarly,
mutating the HMTase domain (E1357K or N1458I) of
drosophila Ash1 prevented the increase of H3K4
methylation at the target site, and subsequently eradicated
the activation of gene expression, as opposed to the wild-
type enzyme (109). With respect to the repressive mark
H3K27me3, creating a catalytic mutant by changing one
aa of the Set domain of the H3K27 MTase vSet (Y105A
or Y105F) was sufﬁcient to prevent the decrease in
reporter gene expression which was observed upon
targeting the wild-type enzyme (82). Also for SUV39H1,
the repressive activity of a construct—where the N-
terminal 76 aa of the enzyme were deleted—was
completely abolished by mutating the catalytic activity
(29). In case of Gal4-G9a, a Set construct could not
induce H3K9 methylation and subsequently had no
effect on gene expression (78). Vice versa, targeting
truncated constructs including the HMT activity (aa 210-
1202 (78)) of the HMTase G9a and even a domain as
small as aa 829-1210 (29) were able to induce H3K9
methylation, and both targeted constructs could efﬁciently
downregulate target gene expression. In general, these
studies provide strong indications that epigenetic marks
can be instructive in gene expression regulation.
Indirect gene expression modulation
Next to enzymes which seem to rely solely on their
catalytic activity for GEM, other enzymes have been
described to possess efﬁcient gene expression modulating
activity despite absence of (or mutations in) the CDs. For
example for Dot1, the H3K79 MTase from yeast, two
mechanisms of derepression can be elucidated, a CD-
dependent and a CD-independent mechanism of action.
The CD-dependent mechanism was conﬁrmed by
targeting of only a small part (aa 172-582: including the
HMT domain) of Dot1, which was still able to derepress a
target gene integrated in the yeast genome, with similar
efﬁciency as full-length Dot1 (110). On the other hand,
targeting of only the N-terminal part (1-237 aa, not
including the HMT domain) of Dot1 also induced
derepression of gene expression, thus via a CD-
independent mechanism. Whereas the CD-dependent
mechanism works via reducing the binding of Sir
proteins (yeast homologs of the mammalian sirtuin
HDAC proteins) to the target through methylation of
H3K79, the recruitment of the HAT Gcn5 appears to be
required for the CD-independent mechanism. In addition,
the N-terminal domain seems to function in positioning
the gene away from the nuclear envelope (where
heterochromatin normally localizes). Similar effects were
observed with hDot1L for which several domains were
targeted (aa 1-340, 1-430 and 318-430) using the same
model system (110). Although aa 1-430 shows the best
effect (better than 1-340), aa 318-430 on its own has no
effect. Interestingly, when a truncated part of hDot1L (aa
1-670, including the HMT domain) was investigated in a
fusion to MLL (130), less efﬁcient induction of H3K79
methylation was observed when compared with MLL-
AF10, which supposedly recruits the full-length
endogenous Dot1L, conﬁrming that other domains of
Dot1L are required for full activity. Therefore, these
reports provide an example of an effector domain
containing functional domains apart from the CD which
also play a role in achieving GEM.
Similarly, mutating the active site of SirT1 did not
abolish all repressive activity. Moreover, deletion of the
N-terminal 268 aa (which does not affect the HDAC
domain) diminished the repressive effect of SirT1,
compared with the full-length enzyme (75). This
observation might be explained by the fact that the
missing part was shown to recruit histone H1b, which
has been associated with heterochromatin. Likewise, a
fusion of TetR to a catalytically inactive mutant of
LSD1 (K661A) was still active, resulting in reduction of
H3K4me2 levels at the target site, be it after longer
exposure of the target site to the mutant enzyme than
for the wild type (77). The authors suggested that the
observed decrease in H3K4me2 levels was a secondary
effect due to induced repression of transcription; recruited
repressor proteins might in turn recruit the wild-type
LSD1. Also for Set2, the histone MTase activity can
only explain part of the repression, since two mutations
(R195G and C201A) in the CD of this H3K36 MTase
both did not abolish repression completely (73). It might
be that a substantial part of repression by Set2 lacking the
active Set domain is caused by the remaining ability to
recruit HDACs, as an association was reported for
another H3K36me2 MTase, Smyd2, with HDAC1 and
Sin3A (83).
Despite the indications described above that catalytic
activity is (at least partially) responsible for the observed
effects on gene expression, examples exist of efﬁcient
GEM by targeting enzymes without CDs and/or catalytic
activity. Illustrative here is an example of Dnmt3a:
although the CD is known to result in DNA methylation
and gene repression, the targeting of the full-length murine
Dnmt3a to a reporter plasmid did not result in DNA
methylation (30). Despite this lack of detectable induced
DNA methylation, repression of reporter gene expression
was observed and, as demonstrated by ChIP, proteins
with repressive functions, including Setdb1 and HDAC1,
were recruited to the promoter site. Thus, in this case, it
seems that silencing of the reporter gene was not caused by
DNA methylation through mDnmt3a, but indirectly by
recruitment of other repressive proteins. Since the
observed repressive complex was also formed on
endogenous promoters of hypermethylated genes, as
demonstrated by ChIP–reChIP, this study underlines the
power of targeting mammalian proteins to initiate a
natural repressive cascade in the mammalian context.
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Regardless of the indirect effect on gene expression, the
editing of a mark might be an absolute requirement in
order for the intervention to be mitotically stable. This
is exempliﬁed by a targeting study in which an Ezh2-
mutant lacking its catalytic Set domain still efﬁciently
repressed transcription to 10% of the control level (81).
As the Gal4-Ezh2 Set fusion protein was not associated
with an increase in H3K27me3 levels at the target site, the
repression by the Set mutant of Ezh2 might be caused by
sterical hindrance through recruitment of binding partners
of the Polycomb repressive complex (PRC2) such as EED
and Suz12. Conﬁrming this hypothesis, targeting EED to
the reporter, using the same system, resulted in gene
silencing to 30% of the control level. Moreover, the
repressive effect is no longer observed upon clearance of
the inducible expression of Gal4-Ezh2 Set. This
transient effect is in striking contrast to the effect
obtained by targeting wild-type Ezh2 which showed both
induction of H3K27 methylation and prolonged
repression of reporter gene expression. Most likely, the
introduction of H3K27me3 and the subsequent cascade
of events, not achieved by the Gal4-Ezh2 Set fusion
protein, are essential for obtaining sustained repression.
Theoretically, the presence of certain (recruiting)
domains within the effector domain can decrease the
efﬁciency of the targeted enzyme by causing the effector
domain to be captured by endogenous proteins before
reaching the intended target site. This was suggested to
explain the failure to repress endogenous reporter gene
expression by targeting full-length H3K9 MTase
Suv39H1 in fusion to a ZF (29). The intact HP1
interaction domain might be captured by endogenous
HP1 proteins in heterochromatin, thereby preventing the
fusion protein from reaching its target. Deletion of the N-
terminal (HP1 interaction domain containing) 76 aa or
149 aa did result in efﬁcient histone methylation and
gene repression of a gene in the chromatin context in a
ZF-targeting study (29). Even though the deletion
construct could not recruit HP1 directly because it
lacked the HP1 interaction domain, H3K9me2 was
observed as far as 1 kb upstream of the ZF binding site,
which suggests that some spreading did occur. This
spreading was mediated by the enzymes recruited by the
induced mark itself and not indirectly through recruitment
of other proteins by the targeted enzyme, as a catalytic
mutant did not demonstrate any enrichment in the
methylation marks at this upstream region. Despite the
successful repression induced by the truncated Suv39H1,
inclusion of parts of the N-terminal domain might help to
reinforce the repressive effect as targeting of only this
domain (aa 1-195) resulted in equally efﬁcient repression
of reporter gene expression compared with targeting of
full-length Suv39H1 in another study (79). Apparently,
in the latter co-transfection study no capturing effect by
endogenous HP1 was observed for Gal4-Suv39H1, as the
full length could efﬁciently repress reporter gene
expression. Interestingly, deletion of the N-terminal 213
aa of drosophila SU(VAR)3-9 (of which the ﬁrst 155 aa
are lacking in the human homolog Suv39H1) rendered the
Gal4 fusion protein ineffective in a co-transfection study
compared with its full length, even though this N-terminal
part does not contain the Set domain (80). For the full-
length enzyme, the strong repressive effect was severely
reduced after addition of an HDAC inhibitor, which
conﬁrms a role for the interaction of the N-terminal
domain with the HDAC RPD3.
The most extensively studied protein with respect to
effects of different domains is the HAT p300 (Figure 2),
where at least three domains seem to inﬂuence gene
expression levels. Targeting aa 964-1922 of p300, which
includes the HAT domain, by fusion to Gal4 is sufﬁcient
to result in activation of reporter gene expression in one
study (98), but not in another (99). Also, targeting of a
similar but somewhat smaller HAT-containing domain of
p300 failed to induce endogenous target gene expression in
an MBD targeting study (18). Interestingly, in these latter
two studies, p300 fusion constructs without the
HAT domain (242-1737 (99) and 1472-1522 (18))
could induce activation of gene expression, even to a
higher extent than the full-length protein. These p300
deletion constructs both contain the N-terminal and
the C-terminal activation domains, known to form
‘enhanceosomes’, which might explain the observed
effects. Indeed, targeting of only the N-terminal
(aa 1-596, but not aa 1-242) or the C-terminal domain
(aa 1737-2414) induced expression, again outperforming
the full-length fusion construct (99). Differences between
effects of similar domains in different studies, however,
are observed and might be explained by the location of
the targeted sites (as will be discussed in the part
‘TOWARD SPECIFIC GENE EXPRESSION
MODULATION—The DNA binding domain’). In this
respect, in another study, targeting of only the activating
N-terminal 1-596 domain, by fusing it to the MBD of
MeCP2, could not induce expression of endogenous
methylated genes (18). Of course there are many other
factors in addition to the location of the targeted site
that are likely to play a role in the observed differences
in effects caused by similar domains of the p300 protein.
For example, the differences in cell lines and constructs (in
particular the DBDs) could determine the controversial
outcomes. However, within every study some domains
of the p300 protein did show an activating effect,
indicating that the experimental set-up was available for
effective GEM to occur by targeted HATs.
Also for CBP, targeting of only the HAT domain and
the CBP2 domain (aa 1099-1877) results in gene activation
to a higher extent than the full-length enzyme (102).
Deletion of aa 1458-1475 within the HAT domain
eliminated the activating effect of the HAT, even when
the CBP2 domain is present. The removal of the CBP2
domain—while leaving the HAT domain intact—
resulted in a slightly decreased activating potential. This
decrease in activating potential might be explained by the
CBP2 domain containing a number of binding sites for co-
activators, although targeting of only the CBP2 domain
did not result in an activating effect (102).
In conclusion, for some epigenetic enzymes GEM is
caused through the direct writing or erasing of epigenetic
marks, whereas for others recruitment of co-activators or
repressors determines functional outcome. However, to
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achieve efﬁcient, sustained effects (mitotic heritability), the
actual editing of epigenetic marks seems warranted.
TOWARD SPECIFIC GENE EXPRESSION
MODULATION
The effector domain
Thus, targeting epigenetic enzymes or domains thereof,
can induce efﬁcient modulation of epigenetic marks
resulting in GEM. Of utmost importance for general
applicability of the approach is the locus speciﬁcity of
the targeted approach. As exempliﬁed by Gal4-targeted
Drosophila Ash1, the targeting of domains does not
necessarily ensure site-speciﬁc effects. The natural Ash1
target gene Ubx, which normally is not expressed in the
experimental model used, was re-expressed as well in
addition to the intended targeted reporter gene (109).
The re-expression of Ubx upon expression of Gal4-
Ash1 was accompanied by induction of H3K4, H3K9
and H4K20 methylation at this endogenous site as also
observed for the intended integrated target site.
Apparently, the Gal4 DBD was not strong enough to
prevent binding of Ash1 to the Ubx gene. In this line of
reasoning, it is also important to realize that certain
epigenetic enzymes, such as HATs and HDACs were
shown to have an effect on non-histone proteins such as
transcription factors (131,132), which might inﬂuence the
cell biological outcome.
Similarly, targeting of DNA methyltransferase M.HhaI
and M.HpaII fused to a four-ﬁnger ZF resulted in
methylation of their coding plasmids in bacteria
although these were devoid of ZF binding sites (52). In
addition, background methylation was reported for
M.SssI (48,49). Contrastingly, the enzyme only efﬁciently
functioned on naked DNA when tethered to the DNA;
efﬁcient methylation was observed for ZF-M.SssI for
oligonucleotides containing the ZF binding site, but not
for oligonucleotides without the ZF binding site (48).
Although the afﬁnity of M.SssI itself for DNA was
decreased upon fusing the enzyme to ZFs, it still seems
to be too high to allow its site of action to be restricted by
DBDs (48). Namely, similar methylation efﬁciencies were
observed for targeted versus untargeted M.SssI in yeast
Figure 2. Targeted gene expression regulation capacity by various domains of p300. This ﬁgure gives an overview of the domains of p300 that were
targeted by fusion to a sequence-speciﬁc DBD. Full-length protein actively upregulated the expression of the target gene in all targeting studies
reviewed here. The activating domains are shown above and the non-activating domains below the full-length protein. The ﬁrst and second indicated
domain, respectively, indicate the bromodomain and the HAT domain of p300 according to a conserved domain search on the NCBI website. Dashes
in the full-length protein show the position of the commercially available ‘HAT domain’ of p300 (Millipore). Numbers indicate aa positions. Black-
dashed lines represent a part of the enzyme deleted in the middle of a protein. References are indicated by the pattern of stripes or color within the
domain box as explained in the legend. The table at the right side indicates whether the N-terminal activation domain, HAT domain and/or C-
terminal activation domain are present in the related construct. Domains indicated with a star shape were more active than the full-length enzyme
upon comparison within one study. Thin dotted lines connect two equal domains with different outcomes.
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cells, for a non-ZF target locus as well as for the targeted
locus (49). Such off-target effects underline the need
for MTases strictly functioning at the predetermined
target.
A promising way to diminish off-target effects of
epigenetic enzymes in targeted fusion proteins is to
engineer less active mutants of the enzyme to be fused to
the DBD. In this respect, we constructed the M.SssI
mutant C141S, with a remaining activity of <5% of the
wild-type activity and conjugated this mutant to a gene-
targeting TFO (50). No other CpGs than two targeted
CpGs were efﬁciently methylated in a region of 700 bp
of the promoter or in an amplicon of 400 bp investigated
within the reporter gene of the plasmid upon
co-incubation in a cell-free system, conﬁrming locus-
speciﬁc DNA methylation. Likewise, diverse mutants
of M.HhaI and M.HpaII have been constructed (52).
For the mutant M.HhaIQ237G, which has a remaining
methylation activity of less than 5% in in vitro enzyme
assays, target-speciﬁc methylation was conﬁrmed by
absence of restriction of the coding plasmid, including the
target site, by methylation sensitive restriction enzymes.
For M.HpaII, an F35H mutant with reduced activity was
created of which the mutated aa normally aids in
positioning the adenine ring of S-adenosylmethionine
(SAM) in the protein binding pocket (52). Also this
mutant shows target-speciﬁc methylation in the same
system. Evidently, the same approach of creating
lower activity/afﬁnity mutants could be used to restrict
activity of histone modifying enzymes to the intended
loci.
As an alternative to constructing mutant enzymes, the
so-called ‘split enzyme approach’ has been explored to
improve the speciﬁcity of targeted methylation. Only
when the split parts of the protein localize at neighboring
sites, the parts of the enzyme can combine and methylate
the target sequence. For M.HhaI, a plasmid encoding two
separate three-ﬁnger ZFs fused to complementary halves
of the enzyme and also containing the ZF target sites was
transformed into Escherichia coli (53). Site-speciﬁc
methylation of the cytosine ﬂanked by the two ZF
binding sites was conﬁrmed by bisulﬁte sequencing. A
recent study demonstrated the phenomenon of fragment
complementation for the CG-speciﬁc methyltransferase
M.SssI, which may open the way for applying the split
enzyme approach for targeting any CpG site without
sequence context limitation (133). Although selectivity
was not fully supported in another M.HhaI split-enzyme
study (134), the approach of splitting enzymes (as
reviewed in reference (135)) might provide a promising
tactic for increasing speciﬁcity of EGE.
Despite off-target effects, several examples exist
where the effect of the targeted enzyme seems to be
restricted, since it only takes place when indeed the
recognition site of the DBD is present. For example,
when targeting human Dnmt3a CD to mitochondrial
DNA, no off-target methylation was shown for two
distant mitochondrial regions, suggesting usefulness of
human Dnmt3a in targeting purposes (56). Likewise,
expression of Gal4-CBP had no effect without Gal4
targets being present in the reporter plasmid in a
cotransfection study (102).
The DNA binding domain
Off-target effects, on the same chromosome and on other
chromosomes, might also be envisioned to occur due to
ﬂexible linkers between the DBD and effector domain in
combination with dynamic movement of chromatin.
Despite a speciﬁc binding of the DBD to its unique
genomic target site, the effector domain might get in
contact with distal sequences due to chromatin folding,
but also due to cis and trans interchromosomal
interactions. The basic reach area of epigenetic enzymes
has been investigated using oligonucleotides containing
DBD recognition sites. In this respect, using oligo-
nucleotides with varying distances (2–32 nt) between the
ZF binding site and the target CpG, methylation induced
by Zif268-M.SssI was shown to occur preferentially at
cytosines 16 or 22 bp upstream of the ZF binding
site (48). Although this preference likely reﬂects the
length of the linker between ZF and DNA MTase (19
aa), linker dependence was not further investigated in
this study. As for Zif268-M.SssI, the ﬂexibility of the
ZF-M.HpaII fusion protein was tested in vitro and
appeared to be limited, again likely dependent on its
linker length (21 aa) (51). A distance of 10–40 bps
between the ZF target site and the M.HpaII recognition
site was most successful for binding and methylation
activity of the fusion protein, with optimums at 13 and
34 bps. At 16 and 17 bps distance, a weaker point was
detected, which might indicate a position unable to be
reached by the effector part of the fusion protein.
Based on the above, the reach area of a ZF-DNA
MTase fusion in cell-free systems is limited. Although
cellular experiments suggest that recruitment of spreading
mechanisms can easily enhance the initial effect, it is of
importance to ensure the ﬁrst hit is efﬁcient. In that
respect, it is necessary to know in which direction the
effect will have to take place, upstream or downstream
of the DBD recognition site, as the site of effect might
be determined by the orientation of the effector domain
relative to the DBD. For example, for ZF-M.SssI, the
direction in which the methylation took place, upstream,
was in line with the position of M.SssI in the ZF fusion
protein (C-terminal) (48). In another study, for ZF-
M.HpaII a preference for methylation of the 30 end of
the target site was observed, which is expected because
of the orientation of the ZF-M.HpaII fusion protein on
the target DNA (52). Also the observed DNA
demethylation upon targeting VP64 was in the expected
direction (61). Such orientation dependency, however,
might not be observed for all constructs as no clear
orientation dependency was observed when targeting a
ZF-Dnmt3a CD fusion to an endogenous gene (57).
In addition, most likely it is necessary to modulate more
different epigenetic marks to obtain a sustainable effect.
As far as known, the effect of targeting two different
epigenetic enzymes to the same repeat of DBD recognition
sites has not been assessed. However, targeting of vErbA
(recruiting the NCoR/SMRT co-repressor complex,
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executing HDAC activities) and the H3K9 MTase G9a to
the same promoter showed an increase of the repressive
effect observed compared with targeting either one of the
proteins alone (29). Despite that it becomes clear from the
above that induction of one epigenetic mark can be
sufﬁcient to cause a cascade of events leading to prolonged
effects on gene expression, more research into combined
targeting of epigenetic writers and/or erasers would be
beneﬁcial, especially within the endogenous chromatin
context.
Depending on the epigenetic enzyme, it is likely that the
genomic site where the effector domain is targeted to
(e.g. relative to the transcription start site) is of
importance in determining the functional outcome. The
target site position at least seems to be playing a role in
the case of HATs, as this might explain the contradiction
between the two studies targeting p300 aa 964-1922. In
one of the studies, the Gal4 binding sites were situated
upstream (99) whereas in the other the sites were
situated downstream (98) of the transcription start site.
Only in the study where the Gal4 binding sites were
situated downstream of the transcription start site, an
activating effect was seen, as also shown for full-length
p300 in a different study (100). Fusion of Gal4 to
P/CAF again only resulted in upregulation of gene
expression after cotransfections when the Gal4 binding
sites were situated downstream, not upstream, of the
transcription start site of the reporter gene. When
the Gal4 binding sites were located upstream, close to
the TATA box, an SP1 binding site was needed for
reporter gene activation by targeted P/CAF (100).
Evidently, not only the characteristics of the fusion
protein, comprising the DBD, the linker and the
epigenetic enzyme, inﬂuence the speciﬁcity and efﬁcacy
of the effect. Rational selection of the target site itself
might also be beneﬁcial. In this respect, native chromatin
context requirements might be identiﬁed in the future
which allow efﬁcient EGE. From the studies described in
this review, it becomes clear that one target site can be
sufﬁcient, underlining the feasibility of targeting epigenetic
enzymes using a single gene-speciﬁc DBD. Actually, a
repeat of target sites is not per se required to improve
the effect of histone modifying enzymes, as similar
repression has been shown by LexA-RPD3 when the
reporter plasmid contained just one LexA binding site
when compared to a reporter plasmid with four LexA
binding sites (73). For Gal4-Suv39H1, adding an
additional Gal4 binding site to the reporter plasmid did
not improve the repressive effect either (79).
CONCLUSION
Apart from the ultimate goals of inducing efﬁcient and
permanent GEM, EGE is likely to provide valuable
insights in cause versus consequence of epigenetic marks
with respect to GEM. It is still a matter of debate whether
DNA methylation and post-translational histone
modiﬁcations inﬂuence the gene expression levels directly
or if they are merely byproducts of transcription (6,7,136).
For example, DNA demethylation was reported to be
associated with active histone marks in post-mitotic
cells, but not with transcriptional activity (137).
Targeting minimal CDs of epigenetic writers (and their
catalytically dead mutants) to deﬁned chromatin
environments allows comparisons determining the effect
of the edited mark on higher order chromatin and on
gene expression. In this respect, EGE might provide a
unique tool to eventually settle this cause versus
consequence debate.
Before EGE can become a straightforward approach,
however, the inﬂuence of the chromatin context on the
dynamics of epigenetics has to be addressed in a
systematic manner. It is expected that the positioning of
the effector domain as well as the promoter type might
affect the ultimate outcome. Similarly, dependent on the
cell type, different regulatory protein complexes might be
recruited to the same epigenetic mark (138), and different
histone (variant) turnover rates and clipping of the histone
tails will determine the transient versus mitotically stable
nature of the induced mark (139). In this context,
Verschure et al. (manuscript in preparation) designed a
coarse-grained stochastic model systematically adding
epigenetic regulatory levels of increased complexity (i.e.
epigenetic enzyme binding, its spreading, subsequent
recruitment of regulatory proteins and chromatin
folding) allowing to simulate and interpret the mechanistic
and dynamic behavior of a nucleosomal stretch to attain a
deﬁned epigenetic composition.
Initial publications showed the promise of EGE for a
handful of genes [MASPIN, Sox2, VEGF-A (29,57,95)]
and from these studies some indications on heritability
(DNA methylation) and spreading (H3K9me) can be
distilled. Importantly, these proof-of-concept studies on
targeted methylation clearly show the intended repressive
effect on gene expression. Although it might be more
challenging to effectively compete with spreading
mechanisms to overwrite repressive histone marks, acc-
essibility of inactive chromatin presents no limitations as
ATFs have been successful in re-expressing silenced and
even imprinted genes (61,140). With recent developments
in the targeted DNA demethylation ﬁeld (21), com-
binations of erasers together with certain writers might
prove potent in this respect. In fact, EGE designed for
upregulation of a gene of interest, is advantageous over
cDNA approaches as with EGE all isoforms can be
produced in their natural ratios and expression levels are
controlled from the natural promoter and through natural
signaling pathways. In addition, silencing via EGE
through appropriate combinations of marks might prove
to be advantageous over approaches like siRNA because
the effect would be sustained after clearance of the drug
(hit and run approach) (57), without saturating/affecting
other cellular (RNAi) processes (39).
With respect to such other gene-speciﬁc gene expression
modulating approaches (gene therapy, RNA interference),
EGE promises several advantages, including the broad
spectrum of delivery possibilities, ranging from chemical
gene-speciﬁc epigenetic inhibitors (141) to direct mRNA
(28) or protein delivery (27,142) of the epigenetic editors.
Eventually, it will be necessary to achieve efﬁcient, cell- or
tissue-speciﬁc delivery of the EGE-device if to be used as
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therapeutic agent. Although this requires further research,
the use of complexes of antibodies recognizing speciﬁc
cells or tissue and a cationic lipid or liposomes might be
powerful approaches to ensure tissue or cell-type
speciﬁcity (143).
The need for novel epigenetic therapies is exempliﬁed by
the numerous ongoing clinical trials to test inhibitors of
epigenetic enzymes (144,145). Although promising,
current (FDA approved) epigenetic drugs severely lack
speciﬁcity not only with respect to the intended target
(also unintended non-chromatin proteins are affected),
but more importantly with respect to the genome-wide
effects (146). The identiﬁcation of epigenetic marks or
combinations of marks which efﬁciently interfere with
gene expression proﬁles will open up new avenues in
biomedical research. As virtually any (undruggable) gene
can be targeted for up- and downregulation (22,28), EGE
adds a novel approach to the biomedical arena to
investigate gene functions, to validate therapeutic targets
and even to be further optimized to become a (synergistic)
therapeutic approach (147).
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